Johnson & Johnson

Johnson & Johnson Expands Procedure-Based Offerings with Bladder Cancer and Vision Advances

Eli Lilly

iShares U.S. Pharmaceuticals ETF

The Risks of Investing in iShares U.S. Pharmaceuticals ETF: A Critical Analysis.

Abbvie

Protagonist

Johnson & Johnson Partners with Protagonist Therapeutics to Compete with AbbVie's Skyrizi

强生

Johnson & Johnson's 15min chart shows MACD Death Cross and KDJ Death Cross.

Johnson & Johnson: A Bullish Stock Amid Market Volatility

Catalyst<ul> <li>Bullish Engulfing and RSI Overbought signals in late February and early March indicate potential rebound momentum for JNJ.</li> <li>Most analysts rate JNJ Strong Buy or Buy, showing strong institutional confidence in the stock.</li> <li>Strong cash reserves and profitability metrics suggest solid fundamental health for the company.</li></ul>Risk<ul> <li>A MACD Death Cross signal on February 23 suggests a potential bearish trend for JNJ.</li> <li>Fund flow data indicates large and extra-large orders are trending negatively, signaling institutional caution.</li></ul>

Key Factors

Johnson & Johnson's FDA-approved Icotyde, an oral IL-23 inhibitor for plaque psoriasis, is positioned to compete with AbbVie's Skyrizi. Johnson & Johnson expanded its procedure-based offerings with promising Phase 1 results for extended release erdafitinib in bladder cancer and FDA approval for TECNIS PureSee intraocular lens for cataract surgery. Johnson & Johnson partnered with Protagonist Therapeutics to develop Icotyde, which received FDA approval after being jointly discovered by the two companies.

Recent Updates

JNJ News